Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 S ...

Federal Reserve Governor Stephen Miran, whose term ends on January 31, argued in a recent Fox Business interview that the Fed should implement well over 100 basis points (or one percentage point) of rate cuts this year to support economic growth. Miran contends that the current monetary policy is clearly restrictive and holding the economy back. He believes underlying inflation is basically at the Fed's 2% target. He has consistently advocated for more aggressive rate reductions, having been the sole dissen ...

精彩内容 抗细菌药物是临床常用的一类药物，同时也是受国采影响较大的品类。米内网数据显示，2024年中国公立医疗机构终端全身用抗细菌化药销售额跌破千 亿，2025年前三季度继续下跌约18%。国采品种霸榜TOP20产品，复方注射剂逆势飙涨219%；8个品种满足国采入围门槛，又有哪些会被纳入新一批国 采？ 抗细菌化药市场承压，这家南京药企起飞 米内网数据显示，近年来中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端全身用抗细菌化药市场承压， 继2024年跌破千亿规模后，2025年前三季度继续下滑约18%至超600亿元。 全身用抗细菌化药涵盖12大治疗小类，其中头孢类稳居首位，但其销售额已4连跌（2022-2025年前三季度）；β-内酰胺类抗菌药/青霉素类、其他抗菌药依 次位列第二、第三，市场份额均超过10%。 2025Q1-Q3中国公立医疗机构终端全身用抗细菌化药TOP5小类 来源：米内网中国公立医疗机构药品终端竞争格局 在一级集团排名中，辉瑞、国药集团、华北制药（维权）稳居前三，2025年前三季度销售额分别超过62亿元、21亿元、19亿元；排位第十五的南京优科生 物表现亮眼，同 ...

This big pharma stock still faces significant challenges in the new year.A rising tide doesn't lift all boats. For example, a boat with gaping holes in its hull will sink regardless of how high the tide rises. Pfizer (PFE 0.59%) seemed to be the investing equivalent of such a boat in 2025.Shares of the pharmaceutical giant declined 6% last year, experiencing several significant fluctuations along the way. Can Pfizer's stock bounce back in 2026? NYSE : PFEPfizerToday's Change( -0.59 %) $ -0.15Current Price$ ...

PENSACOLA, Fla.--(BUSINESS WIRE)--At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, as more than 2,100 women pursue litigation alleging Pfizer failed to adequately warn patients despite long-standing knowledge of the risk. The hearing took place within days of the The US Food and Drug Administration (FDA) approving a label change to Pfizer's contr. ...

分组1 - Credo Technology (CRDO) has a high momentum rating despite a recent drop, with a current rating of B compared to A+ six months ago. The stock has shown significant performance over various periods, including a 101% increase over 12 months versus the sector's 0.36% [6][7][8] - Merck (MRK) is preferred over Pfizer (PFE) due to slightly better momentum and total returns, despite Pfizer having better valuation metrics. Merck's momentum is rated B- compared to Pfizer's C, and it has outperformed Pfizer in returns over the last month, three months, and six months [13][15] - Comfort Systems (FIX) is rated as a hold due to a poor valuation grade (F), despite strong growth (A+) and profitability (A-). The stock's trailing PE is 42 times compared to the sector's 21 times, indicating it is expensive [22][24][25] 分组2 - Energy stocks are sensitive to oil prices, which can lead to changes in fundamentals and ratings. For example, Energy Transfer (ET) has seen its rating drop from strong buy to hold due to declining oil prices [17][20] - The quant analysis system used evaluates stocks based on factors such as value, growth, profitability, momentum, and EPS revisions. Each factor has underlying metrics that are weighted based on their predictive value [31][34] - The top 10 stocks for 2026 have shown strong past performance, with returns significantly outperforming the S&P 500 over various periods. For instance, stocks held from 2024 to December 2025 yielded a return of 356% compared to the S&P's 47% [40][41]

UBS set a price target of $25 for Pfizer (NYSE:PFE), indicating a slight overvaluation based on the current stock price of $25.43.Pfizer's stock has experienced a decline of 2.3% over the past month, underperforming against the Zacks S&P 500 composite and the Zacks Large Cap Pharmaceuticals industry.The company's market capitalization stands at approximately $144.59 billion, with a trading volume of 38,061,592 shares, highlighting significant investor interest.On January 6, 2026, UBS set a price target of $ ...

Group 1 - Envision Research, led by Lucas Ma, has over 20 years of investment experience and specializes in quantitative investment and renewable energy [1] - The firm offers two model portfolios: one focused on short-term survival and withdrawal, and the other on aggressive long-term growth [1] - Envision Early Retirement and Sensor Unlimited provide solutions for generating high income and growth with isolated risks through dynamic asset allocation [1] Group 2 - The firm provides direct access for clients to discuss investment ideas via chat, along with monthly updates on holdings and tax discussions [1] - Envision Research combines extensive experience in high-tech R&D, consulting, and portfolio management to inform its investment strategies [1]

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ... ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $143.2 billion, the company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. The pharmaceutical giant is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Tuesday, Feb. 3. Ahead of the event, analysts ex ...